Shields Kelly M, Hrometz Sandra L
Department of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810-1078, USA.
Ann Pharmacother. 2006 May;40(5):931-4. doi: 10.1345/aph.1G471. Epub 2006 Apr 18.
To review the pathophysiology of female sexual dysfunction (FSD) and the literature regarding the use of sildenafil in its treatment.
Literature was accessed through MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), EMBASE (1966-April 2006), and bibliographies of pertinent articles. Search terms included female sexual dysfunction; sexual dysfunction, psychological; phosphodiesterase inhibitors; and sildenafil.
The lack of a clear understanding of FSD contributes to the limited treatment options available. Studies regarding the safety and efficacy of the phosphodiesterase 5 inhibitor sildenafil in the management of FSD were evaluated. Many trials have been of poor quality, making clinical application of their results difficult. The current literature does not show sildenafil to be an effective treatment option for FSD.
Treatment of FSD should include both physical and psychological components. Based on the limited data available, it appears that sildenafil, while well tolerated, offers little or no benefit to most patients with FSD.
回顾女性性功能障碍（FSD）的病理生理学以及有关使用西地那非治疗该病的文献。
通过MEDLINE（1966年至2006年4月）、爱荷华药物信息服务（1966年至2006年4月）、EMBASE（1966年至2006年4月）以及相关文章的参考文献获取文献。检索词包括女性性功能障碍；心理性性功能障碍；磷酸二酯酶抑制剂；以及西地那非。
对FSD缺乏清晰的认识导致可用的治疗选择有限。对磷酸二酯酶5抑制剂西地那非治疗FSD的安全性和有效性的研究进行了评估。许多试验质量较差，其结果难以在临床中应用。目前的文献并未表明西地那非是FSD的有效治疗选择。
FSD的治疗应包括身体和心理两方面。基于现有的有限数据，西地那非虽然耐受性良好，但对大多数FSD患者几乎没有益处。
